# PLATON: HCP commentary report

> 445 verified statements (108 from clinicians verified by NPI or staff page) from 31 commentary sources · 12 findings · updated Nov 1, 2026

## Report

- Trial: A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]
- NCT ID: NCT03784755
- Registry: https://clinicaltrials.gov/study/NCT03784755
- Sponsor: Canadian Cancer Trials Group
- Phase: Not applicable
- Status: Active, not recruiting
- Drugs tested: none (the trial tests no drug)
- Indication: hormone sensitive oligometastatic prostate cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-01
- Last checked: 2026-11-01
- Release hash: 480aad9887f856ca88a6fe4d6e2bfb0cc6e59b23c8085c3960093518259f4869

## Counts

- HCP commentary sources screened: 47
- Sources cited by verified statements: 31
- Verified statements: 445
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 108
- Findings: 12
- Named people in screened sources (unnamed speakers and accounts not counted): 51
- Voices cited: 51
- Cited voices identity-verified: 47
- Organisational or shared accounts (not counted as people): 2

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

PLATON asks whether adding treatment of metastatic lesions to systemic therapy improves outcomes in hormone-sensitive oligometastatic prostate cancer. Commentary comes from X threads, podcasts and YouTube discussions, with a urologist among the contributors. Debate centers on whether metastasis-directed therapy should be routine care, which endpoints justify its use, and how patient selection should extend beyond technical targetability. Its added contribution alongside contemporary systemic therapy remains an open clinical question.

## Open Medical Affairs question

Which patients gain enough from adding MDT to justify its timing, systemic-treatment burden and local-treatment risks, and which outcomes would demonstrate that value?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Whether MDT is routine care remains contested, with endpoint choice central to the disagreement
- F2. PLATON is valued for testing MDT beyond contemporary systemic therapy, but its clinical impact remains prospective
- F3. PSMA staging can accelerate systemic treatment and funding access without resolving whether the management change improves outcomes
- F4. Selection cannot rest on technical targetability alone: biology, burden, imaging completeness and marrow reserve matter
- F5. Combination-treatment enthusiasm coexists with selective efforts to defer or limit systemic therapy
- F6. An equivocal low-PSA recurrence exposes disagreement over scanning, metastatic classification and the threshold to treat
- F7. The pilot case makes licensing, evidence applicability and treatment interruption consequential parts of the MDT decision
- F8. Occult pelvic disease challenges lesion-only treatment, while symptoms and anatomy preserve selective surgical roles
- F9. Perceived low treatment burden does not remove radiation complications or barriers to SBRT access
- F10. Prostate-primary dose discussions prioritize low toxicity but leave room for definitive treatment in a solitary-metastasis scenario
- F11. Lutetium is discussed as an alternative systemic partner and a sequencing opportunity, not established proof of synergy
- F12. Randomization acceptability, systemic-treatment comparability and funding complicate evidence generation

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 81 | 77 | 14 | 30 | recorded | 3 |
| F2 | 37 | 38 | 11 | 13 | recorded | 3 |
| F3 | 27 | 23 | 4 | 10 | recorded | 3 |
| F4 | 49 | 52 | 8 | 7 | recorded | 4 |
| F5 | 23 | 25 | 5 | 7 | recorded | 4 |
| F6 | 51 | 56 | 2 | 2 | recorded | 4 |
| F7 | 78 | 98 | 2 | 2 | recorded | 3 |
| F8 | 24 | 39 | 3 | 4 | recorded | 3 |
| F9 | 21 | 22 | 3 | 10 | recorded | 3 |
| F10 | 11 | 13 | 1 | 8 | recorded | 2 |
| F11 | 16 | 26 | 2 | 1 | recorded | 3 |
| F12 | 34 | 37 | 6 | 15 | recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 44 | 12 | 6 | 4 | 15 | 86 | 10 | 11 posts and articles, 3 podcasts and video | yes |
| F2 | 15 | 6 | 5 | 5 | 6 | 43 | 4 | 8 posts and articles, 3 podcasts and video | yes |
| F3 | 14 | 7 | 4 | 0 | 2 | 28 | 2 | 2 posts and articles, 2 podcasts and video | yes |
| F4 | 23 | 13 | 6 | 4 | 3 | 65 | 7 | 5 posts and articles, 3 podcasts and video | yes |
| F5 | 14 | 2 | 1 | 1 | 5 | 27 | 4 | 3 posts and articles, 2 podcasts and video | yes |
| F6 | 27 | 7 | 0 | 0 | 17 | 61 | 14 | 2 podcasts and video | yes |
| F7 | 24 | 13 | 14 | 7 | 20 | 114 | 11 | 2 podcasts and video | yes |
| F8 | 9 | 3 | 2 | 3 | 7 | 46 | 0 | 3 podcasts and video | yes |
| F9 | 8 | 1 | 9 | 0 | 3 | 22 | 1 | 1 post or article, 2 podcasts and video | yes |
| F10 | 9 | 1 | 1 | 0 | 0 | 13 | 1 | 1 post or article | yes |
| F11 | 9 | 0 | 0 | 1 | 6 | 27 | 1 | 2 podcasts and video | yes |
| F12 | 22 | 9 | 1 | 1 | 1 | 36 | 1 | 4 posts and articles, 2 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: Failure-free Survival: F1 (1 shared claims), F2 (2 shared claims)
- Secondary endpoints: F1 (19 shared claims), F2 (3 shared claims), F9 (2 shared claims), F12 (2 shared claims)
- Population and setting: F1 (2 shared claims), F2 (4 shared claims), F4 (39 shared claims), F5 (2 shared claims)
- The comparison: F1 (4 shared claims), F2 (12 shared claims), F3 (2 shared claims), F5 (12 shared claims), F6 (2 shared claims), F12 (7 shared claims)
- Safety and tolerability: F1 (6 shared claims), F4 (6 shared claims), F8 (3 shared claims), F9 (10 shared claims), F10 (3 shared claims), F11 (1 shared claims)
- Design and conduct: F1 (8 shared claims), F2 (30 shared claims), F12 (14 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. PLATON is valued for testing MDT beyond contemporary systemic therapy, but its clinical impact remains prospective

An X-thread participant asks which outcome PLATON uses as its primary endpoint.

Dates are the thread’s post dates.

The exchange concerns trial design, not PLATON efficacy or safety results.

Source: X thread, 2019-10-19.

### F1. Whether MDT is routine care remains contested, with endpoint choice central to the disagreement

Within an X-thread discussion mentioning PLATON, a participant asks whether progression-free survival is sufficient to assess metastasis-directed therapy, or whether metastasis-free or overall survival is needed.

Dates are the thread’s post dates.

The endpoint question concerns the broader metastasis-directed therapy discussion, not reported PLATON outcomes.

Source: X thread, 2021-04-23.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 24 sections | Paid |
| Verified statements with short source quotes and links | 445 | Paid |
| Trial aspects mapped | 14 | Free |
| Sources with links | 31 | Counts free |
| Speaker attribution for cited voices | 51 | Paid |

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Failure-free Survival | discussed | 3 | 2 |
| Secondary endpoints | discussed | 26 | 10 |
| Population and setting | discussed | 47 | 12 |
| The comparison | discussed | 39 | 13 |
| Safety and tolerability | discussed | 22 | 5 |
| Design and conduct | discussed | 52 | 14 |
| PSMA stage migration, prognostic work-up and access-dependent systemic treatment | discussed | 26 | 4 |
| Systemic intensification versus selective ADT-sparing or delayed-treatment approaches | discussed | 39 | 7 |
| Equivocal PET findings and the decision to observe, classify or treat recurrent disease | discussed | 51 | 2 |
| Occupational consequences, patient priorities and intermittent treatment in the pilot case | discussed | 78 | 2 |
| Lesion-only versus pelvic-field treatment and selective roles for surgery | discussed | 24 | 3 |
| Prostate-primary radiation dose, fractionation and disputed schedule interpretations | discussed | 11 | 1 |
| Lutetium as an MDT partner, mechanistic uncertainty and prospective priming strategies | discussed | 16 | 2 |
| Treatment access, trial acceptability and the economics of comparator selection | discussed | 45 | 7 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 41 | 28 |
| Podcasts | 3 | 2 |
| YouTube | 2 | 1 |
| Bluesky threads | 1 | 0 |

- Screened window: 2018-10-31 to 2026-10-26
- Cited window: 2018-10-31 to 2026-10-08
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]
- Registry: NCT03784755 (https://clinicaltrials.gov/study/NCT03784755)
- Study IDs: PR20
- Sponsor: Canadian Cancer Trials Group
- Collaborators: Canadian Cancer Society (CCS)
- Design: Not applicable · interventional, randomized, parallel, na
- Status: Active, not recruiting
- Enrollment: 409 (actual)
- Start: 2019-11-15 (actual)
- Primary completion: 2032-12-31 (estimated)
- Primary endpoint: Failure-free Survival (12 years)
- Intervention: Ablative Radiation Therapy (radiation)
- Intervention: Standard of care (other)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- The source search did not run to completion, so some matching discussion may be missing.
- Not yet captured in this edition: a view on guideline-based preference for PSMA PET/CT over conventional imaging when available for metastatic work-up.
- Not yet captured in this edition: a view on balancing lesion-directed treatment and androgen deprivation with occupational requirements.
- Not yet captured in this edition: a view on oligometastatic eligibility and sequencing systemic treatment with local ablative therapy.
- Not yet captured in this edition: a view on insurance denials obstructing both PET and subsequently recommended conventional imaging for treatment work-up.
- Not yet captured in this edition: a view on PSMA-guided treatment selection and systemic therapy for PET-detected metastases despite negative conventional imaging.
- Not yet captured in this edition: a question about clinical markers and imaging for selecting patients who might benefit from adding lutetium to stereotactic radiotherapy.
- Not yet captured in this edition: a view on balancing metastasis-directed therapy and androgen deprivation with occupational needs and trial-dependent systemic intensification.
- Not yet captured in this edition: a view on ARPI unsuitability without a stated reason for the assessment.
- Not yet captured in this edition: a view on imaging access and funding in staging and treatment selection for oligometastatic prostate cancer.
- Not yet captured in this edition: a view on how imaging funding and local access enable PET-first staging and inform treatment choices for occult metastases.
- Not yet captured in this edition: a remark on imaging funding and local access conditions preceding treatment decisions for PET-only metastases.
- Not yet captured in this edition: a view on lifelong systemic therapy versus metastasis-directed surgery or radiotherapy in hormone-sensitive oligometastatic prostate cancer.
- Not yet captured in this edition: a view on retaining ADT as a systemic-treatment option when an ARPI is withheld.
- Not yet captured in this edition: a question about focal versus regional nodal irradiation and local-treatment selection when bone metastases coexist.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 204 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition do not represent all HCPs or all public discussion. Source totals, reposts and audience polls cannot establish the number of independent clinicians supporting a position or its prevalence.
- Podcast and video versions contain overlapping discussion. Repeated words are not additional agreement, and several passages cannot confidently be assigned to a named speaker.
- Discussion not naming PLATON, alternative spellings and other references may be missing. Some relevant passages were not fully assessed, particularly treatment-withholding exceptions, ARPI suitability and administration difficulties, imaging access, and selection or sequencing for lutetium with SBRT.
- No separate PLATON protocol document or results publication was identified. Descriptions of its methods, completion and anticipated importance are attributed commentary, not reported efficacy or safety findings.
- Evidence from other trials, pooled analyses, presentations and individual patients is not PLATON evidence. Differences in hormone sensitivity, recurrence timing, imaging, systemic treatment and endpoints limit transfer to PLATON's clinical question.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The sources describe two speakers as involved in PLATON. Their views should be read with that source-described involvement, not counted as independent external assessments of the trial.
- Versions of the recurrent-patient discussion differ in naming the comparison study as mBARC or EMBARK and in describing whether ADT plus darolutamide was funded. These differences prevent a single confident account of the study analogy or treatment access.
- Enrollment numbers and expected timelines vary between statements. Relative completion dates, anticipated readouts and personal forecasts are preserved as expressed and should not be treated as a reconciled trial timeline.
- Some brief remarks and treatment terms are unclear. They do not establish a specific regimen, complication treatment, clinical rationale or formal regulatory requirement.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-11-01: current edition

Last checked for new commentary 2026-11-01. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Deep (445 verified statements)
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $3,400
- 6 months of weekly updates: $4,900
- 12 months of weekly updates: $6,800
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (47 now), at most $1,950; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/platon-nct03784755
- Agents: POST https://www.erudio.com/api/orders with {"report": "platon-nct03784755", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=platon-03784755

## Cite

Erudio Health. PLATON (NCT03784755): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 1, 2026. https://www.erudio.com/reports/platon-nct03784755

## Machine access

- JSON: https://www.erudio.com/reports/platon-nct03784755.json
- Markdown: https://www.erudio.com/reports/platon-nct03784755.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "platon-03784755"}`